M. Gürbüz Et Al. , "Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group," Journal of Gastrointestinal Cancer , vol.53, no.2, pp.282-288, 2022
Gürbüz, M. Et Al. 2022. Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. Journal of Gastrointestinal Cancer , vol.53, no.2 , 282-288.
Gürbüz, M., Akkuş, E., Sakin, A., Urvay, S., Demiray, A. G., Şahin, S., ... Şakalar, T.(2022). Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. Journal of Gastrointestinal Cancer , vol.53, no.2, 282-288.
Gürbüz, Mustafa Et Al. "Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group," Journal of Gastrointestinal Cancer , vol.53, no.2, 282-288, 2022
Gürbüz, Mustafa Et Al. "Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group." Journal of Gastrointestinal Cancer , vol.53, no.2, pp.282-288, 2022
Gürbüz, M. Et Al. (2022) . "Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group." Journal of Gastrointestinal Cancer , vol.53, no.2, pp.282-288.
@article{article, author={Mustafa Gürbüz Et Al. }, title={Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group}, journal={Journal of Gastrointestinal Cancer}, year=2022, pages={282-288} }